Skip to main content
Current Cancer Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes, genes.
Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in cancer.
As the discovery, identification, characterization and validation of novel human drug targets for anti-cancer drug discovery continues to grow; this journal has become essential reading for all pharmaceutical scientists involved in drug discovery and development.

Publisher: Bentham Science Publishers

More about this publication?
Volume 10, Number 1, 2010

Articles

Favourites:
ADD
Favourites:
ADD

Biological Agents Involved in Malignant Mesothelioma: Relevance as Biomarkers or Therapeutic Targets
pp. 19-26(8)
Authors: Crispi, S.; Cardillo, I.; Spugnini, E. P.; Citro, G.; Menegozzo, S.; Baldi, A.

Favourites:
ADD

γ  T Cell Modulation in Anticancer Treatment
pp. 27-36(10)
Authors: Caccamo, N.; Dieli, F.; Meraviglia, S.; Guggino, G.; Salerno, A.

Favourites:
ADD

Targeting Vascular Endothelial Growth Factor Pathway in First-Line Treatment of Metastatic Colorectal Cancer: State-of-the-Art and Future Perspectives in Clinical and Molecular Selection of Patients
pp. 37-45(9)
Authors: Loupakis, F.; Bocci, G.; Pasqualetti, G.; Fornaro, L.; Salvatore, L.; Cremolini, C.; Masi, G.; Danesi, R.; Tacca, M. D.; Falcone, A.

Favourites:
ADD

Can we Consider Zoledronic Acid a New Antitumor Agent? Recent Evidence in Clinical Setting
pp. 46-54(9)
Authors: Santini, D.; Virzi, V.; Fratto, M. E.; Bertoldo, F.; Sabbatini, R.; Berardi, R.; Calipari, N.; Ottaviani, D.; Ibrahim, T.

Favourites:
ADD

Bortezomib: A New Pro-Apoptotic Agent in Cancer Treatment
pp. 55-67(13)
Authors: Russo, A.; Bronte, G.; Fulfaro, F.; Cicero, G.; Adamo, V.; Gebbia, N.; Rizzo, S.

Favourites:
ADD

Molecular Predictors of Efficacy to Anti-EGFR Agents in Colorectal Cancer Patients
pp. 68-79(12)
Authors: Ruzzo, A.; Graziano, F.; Canestrari, E.; Magnani, M.

Favourites:
ADD

CETUXIMAB: From Bench to Bedside
pp. 80-95(16)
Authors: Vincenzi, B.; Zoccoli, A.; Pantano, F.; Venditti, O.; Galluzzo, S.

Favourites:
ADD

Bid Mediates Anti-Apoptotic COX-2 Induction Through the IKKβ/NFκB Pathway Due to 5-MCDE Exposure
pp. 96-106(11)
Authors: Luo, W.; Li, J.; Zhang, D.; Cai, T.; Song, L.; Yin, X.-M.; Desai, D.; Amin, S.; Chen, J.; Huang, C.

Favourites:
ADD

Biomolecular Pathogenesis of Borderline Ovarian Tumors: Focusing Target Discovery Through Proteogenomics
pp. 107-116(10)
Authors: Vergara, D.; Tinelli, A.; Martignago, R.; Malvasi, A.; Chiuri, V. E.; Leo, G.

Favourites:
ADD

Stat3 Orchestrates Tumor Development and Progression: The Achilles' Heel of Head and Neck Cancers?
pp. 117-126(10)
Authors: Masuda, M.; Wakasaki, T.; Suzui, M.; Toh, S.; Joe, A. K.; Weinstein, I. B.

Favourites:
ADD

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content